Graham Collins
Associate Professor of Haematology
Professor Collins is Associate Professor of Haematology and has academic interests in Hodgkin and high grade non-Hodgkin lymphoma. He is the deputy chair of that national Lymphoma trials group and is chief investigator for a number of investigator initiated and commercial trials.
Recent publications
-
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry.
Marchetti M. et al, (2023), Ther Adv Hematol, 14
-
Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway.
Zhang X-Y. and Collins GP., (2022), Curr Oncol Rep, 24, 1477 - 1488
-
HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL).
Carlo-Stella C. et al, (2022), Clin Lymphoma Myeloma Leuk, 22 Suppl 2
-
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
Kuhnl A. et al, (2022), Br J Haematol, 198, 492 - 502
-
Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Henriksen PA. et al, (2022), Circ Heart Fail, 15